Tscan Therapeutics Inc

NASDAQ:TCRX 3:59:00 PM EDT

1.84

+0.04 (+2.22%)

7:47:32 PM EDT: $1.85 +0.01 (+0.54%)

Market Cap (Intraday)	34.84M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$4.1 Million
Adjusted EPS	-$0.72

See more estimates

10-Day MA	$1.83
50-Day MA	$1.90
200-Day MA	$2.72

See more pivots

Tscan Therapeutics Inc Stock, NASDAQ:TCRX

830 Winter Street, Waltham, Massachusetts 02451

United States of America

Phone: +1.857.399.9500

Number of Employees: 105

http://www.tscan.com

Description

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.